Teva Pharmaceutical Industries Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Teva Pharmaceutical Industries wird ein jährliches Gewinn- und Umsatzwachstum von 40.5% bzw. 2.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 39.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 29.1% betragen.
Wichtige Informationen
40.5%
Wachstumsrate der Gewinne
39.6%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 27.6% |
| Wachstumsrate der Einnahmen | 2.6% |
| Zukünftige Eigenkapitalrendite | 29.1% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 12 Jun 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14
Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
Sep 28Teva Pharmaceutical: Past Behind And A Promising 2023
Sep 16Teva wins European approval for biosimilar to Roche’s eye therapy Lucentis
Aug 29These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt Extensively
Aug 05Teva flags supply constraints to ADHD drug Adderall as demand rises - Bloomberg
Aug 03Forex volatility, performance of generic drugs, opioid settlements in focus for Teva's Q2 earnings
Jul 26Teva again in the sights of New York Attorney General over alleged role in opioid crisis
Jul 11Teva names new medical chief
Jul 01Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week
Jun 20Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 17,048 | 1,610 | 3,403 | 2,196 | 9 |
| 12/31/2025 | 16,625 | 1,375 | 3,097 | 2,424 | 10 |
| 12/31/2024 | 16,002 | 809 | 2,375 | 338 | 10 |
| 3/31/2024 | 16,004 | -478 | 878 | 1,389 | N/A |
| 12/31/2023 | 15,846 | -559 | 842 | 1,368 | N/A |
| 9/30/2023 | 15,273 | -2,317 | 608 | 1,157 | N/A |
| 6/30/2023 | 15,017 | -2,342 | 1,173 | 1,695 | N/A |
| 3/31/2023 | 14,925 | -1,711 | 964 | 1,494 | N/A |
| 12/31/2022 | 14,925 | -2,446 | 1,042 | 1,590 | N/A |
| 9/30/2022 | 15,141 | -1,291 | 514 | 1,073 | N/A |
| 6/30/2022 | 15,433 | -1,054 | 476 | 1,059 | N/A |
| 3/31/2022 | 15,557 | -615 | 585 | 1,154 | N/A |
| 12/31/2021 | 15,878 | 417 | 236 | 798 | N/A |
| 9/30/2021 | 16,231 | 726 | 88 | 673 | N/A |
| 6/30/2021 | 16,324 | -3,915 | -131 | 451 | N/A |
| 3/31/2021 | 16,284 | -3,982 | -94 | 506 | N/A |
| 12/31/2020 | 16,659 | -3,990 | 638 | 1,216 | N/A |
| 9/30/2020 | 16,673 | -4,031 | 902 | 1,423 | N/A |
| 6/30/2020 | 16,788 | 4 | 894 | 1,441 | N/A |
| 3/31/2020 | 17,095 | -825 | 413 | 941 | N/A |
| 12/31/2019 | 16,887 | -999 | 223 | 748 | N/A |
| 9/30/2019 | 16,396 | -4,048 | -42 | 577 | N/A |
| 6/30/2019 | 16,831 | -4,007 | 84 | 673 | N/A |
| 3/31/2019 | 17,355 | -3,559 | 449 | 1,062 | N/A |
| 12/31/2018 | 18,271 | -2,399 | 1,795 | 2,446 | N/A |
| 9/30/2018 | 19,693 | -11,059 | 2,233 | 2,938 | N/A |
| 6/30/2018 | 20,781 | -10,256 | 2,534 | 3,312 | N/A |
| 3/31/2018 | 21,800 | -16,050 | 2,750 | 3,585 | N/A |
| 12/31/2017 | 21,853 | -16,525 | N/A | 2,225 | N/A |
| 9/30/2017 | 23,479 | -5,963 | N/A | 2,791 | N/A |
| 6/30/2017 | 23,425 | -6,145 | N/A | 3,457 | N/A |
| 3/31/2017 | 22,743 | 78 | N/A | 3,985 | N/A |
| 12/31/2016 | 21,903 | 68 | N/A | 3,890 | N/A |
| 9/30/2016 | 20,292 | 1,591 | N/A | 5,415 | N/A |
| 6/30/2016 | 19,552 | 1,346 | N/A | 5,047 | N/A |
| 3/31/2016 | 19,480 | 1,697 | N/A | 5,564 | N/A |
| 12/31/2015 | 19,652 | 1,573 | N/A | 5,542 | N/A |
| 9/30/2015 | 19,939 | 1,775 | N/A | 5,679 | N/A |
| 6/30/2015 | 20,174 | 2,548 | N/A | 6,010 | N/A |
| 3/31/2015 | 20,253 | 2,757 | N/A | 5,583 | N/A |
| 12/31/2014 | 20,272 | 3,055 | N/A | 5,127 | N/A |
| 9/30/2014 | 20,534 | 2,748 | N/A | 4,191 | N/A |
| 6/30/2014 | 20,535 | 2,583 | N/A | 3,211 | N/A |
| 3/31/2014 | 20,414 | 1,383 | N/A | 3,033 | N/A |
| 12/31/2013 | 20,314 | 1,269 | N/A | 3,237 | N/A |
| 9/30/2013 | 20,133 | 1,209 | N/A | 3,998 | N/A |
| 6/30/2013 | 20,046 | 419 | N/A | 4,602 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: TEVA wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).
Ertrag vs. Markt: TEVA wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: TEVA wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: TEVADie Einnahmen des Unternehmens (2.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).
Hohe Wachstumseinnahmen: TEVADie Einnahmen des Unternehmens (2.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: TEVADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (29.1%)